Search Results
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
100%, with a mOS of 40.7 months.6In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission
More news about: Vcare PharmaTech
Jun 04, 2026, 22:45 ET WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
and Manufacturing Science and Technology (MSAT) labs, significantly expanding the Company's end-to-end DP capabilities. With three pre-filled syringe (PFS) lines and two vial lines for liquid and lyophilized products, it will deliver integrated DP manufacturing for multiple dosage forms across clinical
More news about: WuXi Biologics
Jun 04, 2026, 16:39 ET Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). Both the vial and PFS presentations are approved in both strengths available for Lucentis®, 0.3 mg (0.05 mL of 6 mg/mL), and 0.5 mg (0.05 mL of 10 mg/mL). Ranibizumab
More news about: Lupin Pharmaceutical, Inc.
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68
More news about: Pomerantz LLP
Jun 04, 2026, 04:35 ET World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
18.2-positive, locally advanced unresectable or metastatic G/GEJA who have received at least two prior systemic therapies. The primary endpoints of the study are PFS and overall survival (OS). The clinical study data are planned to be published in future academic conferences or journals.Professor Lin Shen,
More news about: Innovent Biologics
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
ORR of 78.3% at doses of 200–300 mg/day in CLL patients previously treated with BTK inhibitors, with an estimated median progression-free survival (PFS) of 28.1 months in the 100–300 mg/day dose range[3]. In January 2026, the global Phase III head-to-head clinical trial comparing rocbrutinib
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 21:52 ET 2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma
of GC101 in patients with advanced melanoma who have failed prior PD-1 antibody therapy, with the primary endpoint being progression-free survival (PFS).Juncell's GC101 TIL Therapy Demonstrates Exceptional EfficacyAll enrolled patients in MIZAR-003 had advanced melanoma that failed
More news about: Juncell Therapeutics
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
DLBCL after one or more lines of systemic therapy. The study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed
More news about: ADC Therapeutics SA
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
Japan). Der primäre Endpunkt der Studie ist das Gesamtüberleben (OS). Zu den wichtigsten sekundären Endpunkten zählen das progressionsfreie Überleben (PFS) sowie patientenberichtete Ergebnisse (PROs), darunter krankheitsbezogene Symptome, körperliche Funktionsfähigkeit und Lebensqualität.3 Die
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
Japonsku). Primárnym sledovaným ukazovateľom štúdie bolo celkové prežívanie (OS). Medzi kľúčové sekundárne ukazovatele patrili prežívanie bez progresie (PFS) a výsledky hlásené samotnými pacientmi (PRO) vrátane symptómov súvisiacich s ochorením, telesnej funkčnosti a kvality života.3 Výsledky štúdie
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
amrubicin v Japonsku). Primárním měřítkem výsledku studie je OS. Mezi klíčová sekundární měřítka patří přežití bez progrese (progression-free survival, PFS) a výsledky hlášené pacienty (patient-reported outcomes, PRO), včetně symptomů souvisejících s onemocněním, fyzických funkcí a kvality života.3 Výsledky
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
Pierwszorzędowym punktem końcowym był czas przeżycia całkowitego (OS). Do drugorzędowych punktów końcowych należały czas przeżycia wolnego od progresji choroby (PFS) oraz wyniki zgłaszane przez pacjentów (PRO), obejmujące objawy choroby, funkcjonowanie fizyczne i jakość życia [3]. Wyniki badania DeLLphi-304 zaprezentowano
More news about: Amgen
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
of pirtobrutinib to venetoclax plus rituximab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS). These results were also selected to be featured in the EHA press program.Ajax Therapeutics:In an
More news about: Eli Lilly and Company
Jun 01, 2026, 18:16 ET /C O R R E C T I O N -- Ranok Therapeutics/
follow-up demonstrated durable clinical benefit. Progression-free survival (PFS) data for the optimized 1200 mg QD cohort remain immature and continue to mature. In the pooled lower-dose cohorts (400–1000 mg QD), RNK08954 achieved a median PFS of 7.6 months (95% CI, 2.8–NR). Robust molecular responses were evidenced
More news about: Ranok Therapeutics
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
South Korea; and amrubicin in Japan). The primary outcome measure of the trial is OS. Key secondary outcome measures include progression-free survival (PFS) and patient-reported outcomes (PROs) including disease-related symptoms, physical function, and quality of life.3 Results from DeLLphi-304
More news about: Amgen
Jun 01, 2026, 11:00 ET IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
primary endpoint to support accelerated approval is median progression-free survival (PFS) as assessed by blinded independent central review (BICR). Secondary endpoints include safety and investigator assessed PFS, overall response rate (ORR), disease control rate (DCR) and duration of response. Data
More news about: IDEAYA Biosciences, Inc.
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
(n=32 evaluable participants) reported promising signals:Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months."These data provide important insights into the use of a targeted ADC for the difficult-to-treat rare
More news about: Servier Pharmaceuticals
Jun 01, 2026, 07:00 ET Thesis Gold & Silver Strengthens Team with Appointment of Dimitry Demianyuk as EVP Project Development
start-up. He most recently served as Vice President, Project Development at Discovery Silver, where he led the delivery of the Cordero Project's PEA, PFS, and Feasibility Study, helping advance one of Mexico's largest next-generation greenfield silver development projects.Mr. Demianyuk was also
More news about: Thesis Gold & Silver Inc.
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
benefit; overall mPFS across all 21 efficacy-evaluable patients was 5.8 months (95% CI: 2.2 – NA);5 patients had a PFS of > 20 months including 1 patient with > 30 months PFS;Of the 24/25 pts evaluable for dose limiting toxicities (DLTs), only 1 case of reversible Gr 3 capillary
More news about: Citius Oncology, Inc.
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with conventional chemotherapy, suggesting a potential new treatment option for patients whose disease has progressed
More news about: Hengrui Pharma
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
was not reached. The one patient without target lesions maintained stable for 20.9 months. Among the 5 patients, the median progression-free survival (PFS) since 1L therapy was 20.9 months. Among these, 2 patients, with significant clinical benefit, underwent surgical resection after satri-cel therapy.
More news about: CARsgen Therapeutics
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
(N=11), and 95.0% in patients with PD-L1 TPS ≥50% (N=20), respectively. The overall DCR was 97.9%. The median PFS was not reached (95% CI: 8.4, NR), with a 6-month PFS rate of 74.6% and a 12-month PFS rate of 53.7%. Median OS was not reached, with a 12-month OS rate of 88.8%. As of the data cutoff, 82.7%
More news about: D3 Bio
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg Q3W dose group, the median PFS reached 10.1 (95%CI 6.0, 14.0) months, and the median OS achieved 18.2 (95%CI 10.7, NE; maturity 48.4%) months, with a 24-month OS rate of 47.8% (95%CI
More news about: Innovent Biologics
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option
More news about: TiumBio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
INDIGO trial, include:Median progression-free survival (PFS) per blinded independent review committee (BIRC) was 44.1 months (95% CI, 27.7-not estimable [NE]) in patients treated with VORANIGO. PFS was the primary endpoint of the trial.The median time to next intervention
More news about: Servier Pharmaceuticals